Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 46 AL 60

Mesenchymal stem cell-derived extracellular vesicles: a glimmer of hope in treating Alzheimer's disease

Liew LC, Katsuda T, Gailhouste L, Nakagama H, Ochiya T.

Int Immunol. 2017 Jan 1;29(1):11-19. doi: 10.1093/intimm/dxx002.

Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial

Morris JK, Vidoni ED, Johnson DK, Van Sciver A, Mahnken JD, Honea RA, Wilkins HM, Brooks WM, Billinger SA, Swerdlow RH, Burns JM.

PLoS One. 2017 Feb 10;12(2):e0170547. doi: 10.1371/journal.pone.0170547. eCollection 2017.

Therapeutics of Neurotransmitters in Alzheimer's Disease

Kandimalla R, Reddy PH.

J Alzheimers Dis. 2017;57(4):1049-1069. doi: 10.3233/JAD-161118.

Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data

Yoshida K, Roberts R, Suzuki T, Lebowitz B, Reeves S, Howard R, Abe T, Mimura M, Uchida H.

Am J Geriatr Psychiatry. 2017 Jul;25(7):708-716. doi: 10.1016/j.jagp.2017.01.016. Epub 2017 Jan 30.

Cognitive Training Interventions for Patients with Alzheimer's Disease: A Systematic Review

Kallio EL, Öhman H, Kautiainen H, Hietanen M, Pitkälä K.

J Alzheimers Dis. 2017;56(4):1349-1372. doi: 10.3233/JAD-160810.

Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study

Tai SY, Chen CH, Chien CY, Yang YH.

BMC Neurol. 2017 Feb 23;17(1):40. doi: 10.1186/s12883-017-0800-y.

Editorial: Current and Emerging Therapeutics in AD

Sabbagh M, Decourt B.

Curr Alzheimer Res. 2017;14(4):354-355. doi: 10.2174/156720501404170217182758.

Biophenols pharmacology against the amyloidogenic activity in Alzheimer's disease

Omar SH.

Biomed Pharmacother. 2017 May;89:396-413. doi: 10.1016/j.biopha.2017.02.051. Epub 2017 Feb 27.

Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease

Calhoun A, Ko J, Grossberg GT.

Expert Opin Emerg Drugs. 2017 Mar;22(1):101-105. doi: 10.1080/14728214.2017.1293651.

Mitochondria-Targeted Molecules as Potential Drugs to Treat Patients With Alzheimer's Disease

Reddy AP, Reddy PH.

Prog Mol Biol Transl Sci. 2017;146:173-201. doi: 10.1016/bs.pmbts.2016.12.010. Epub 2017 Feb 11.

Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs

Caraci F, Sultana J, Drago F, Spina E.

CNS Neurol Disord Drug Targets. 2017;16(4):501-513. doi: 10.2174/1871527316666170303144817.

Therapeutic potential of nuclear receptor agonists in Alzheimer's disease

Moutinho M, Landreth GE.

J Lipid Res. 2017 Oct;58(10):1937-1949. doi: 10.1194/jlr.R075556. Epub 2017 Mar 6.

Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches

Rüb U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf HW.

J Alzheimers Dis. 2017;57(3):683-696. doi: 10.3233/JAD-161102.

Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§

Milelli A, De Simone A, Ticchi N, Chen HH, Betari N, Andrisano V, Tumiatti V.

Curr Med Chem. 2017;24(32):3522-3546. doi: 10.2174/0929867324666170309123920.

Mechanisms of Melatonin in Alleviating Alzheimer's Disease

Shukla M, Govitrapong P, Boontem P, Reiter RJ, Satayavivad J.

Curr Neuropharmacol. 2017;15(7):1010-1031. doi: 10.2174/1570159X15666170313123454.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias